FDMT
4D Molecular Therapeutics, Inc. [FDMT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
FDMT Stock Summary
Top 10 Correlated ETFs
FDMT
Top 10 Correlated Stocks
FDMT
In the News
4D Molecular Therapeutics: Promising Preliminary Safety And Efficacy For 4D-310
With its strong focus on product design and development excellence, as evidenced by its sustained success in IND clearance, 4D Molecular Therapeutics is a promising biotech company with significant growth. 4D Molecular Therapeutics' recently released data from its PRISM clinical trial for wet age-related macular degeneration (wet AMD) further validates its R100 intravitreal vector's potential for treating large-market eye diseases.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™
EMERYVILLE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT'), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced that the Company will host a live webcast on February 22 to present interim clinical data from its 4D-310 INGLAXA Phase 1/2 clinical trials for the treatment of Fabry disease cardiomyopathy and will give an update on clinical development plans.
4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
FDMT is an undercovered gene therapy developer. It claims certain competitive differences for its vector delivery platform.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
Recent analyst upgrades suggest these stocks can triple your money or better.
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why
4D Molecular's (FDMT) progress with the development of its pipeline candidates in cystic fibrosis and wet AMD indications have been significant catalysts for the stock.
Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?
4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor conferences:
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -11.54% and 94.60%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
FDMT Financial details
FDMT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.95 | 0.56 | 2.12 | 2.81 | 0 | |
| Net income per share | -0.64 | -3.94 | -8.82 | -11.09 | -3.32 | |
| Operating cash flow per share | -1.1 | -2.93 | -7.92 | -10.75 | -2.68 | |
| Free cash flow per share | -1.12 | -3.19 | -8.07 | -12.17 | -3.04 | |
| Cash per share | 6.19 | 3.97 | 43.03 | 38.53 | 6.6 | |
| Book value per share | -1.86 | -5.83 | 39.87 | 49.62 | 7.15 | |
| Tangible book value per share | -1.86 | -5.83 | 39.87 | 49.62 | 7.15 | |
| Share holders equity per share | -1.86 | -5.83 | 39.87 | 49.62 | 7.15 | |
| Interest debt per share | 0 | 0 | 0 | 2.56 | 0.5 | |
| Market cap | 600.83M | 506.99M | 266.55M | 141.09M | 718.52M | |
| Enterprise value | 509.07M | 457.33M | -10.18M | 4.53M | 682.29M | |
| P/E ratio | -62.91 | -10.28 | -4.7 | -1.98 | -6.68 | |
| Price to sales ratio | 42.52 | 72.57 | 19.58 | 7.82 | 0 | |
| POCF ratio | -36.97 | -13.81 | -5.24 | -2.04 | -8.29 | |
| PFCF ratio | -36.05 | -12.7 | -5.13 | -1.8 | -7.32 | |
| P/B Ratio | -21.78 | -6.95 | 1.04 | 0.44 | 3.11 | |
| PTB ratio | -21.78 | -6.95 | 1.04 | 0.44 | 3.11 | |
| EV to sales | 36.03 | 65.46 | -0.75 | 0.25 | 0 | |
| Enterprise value over EBITDA | -57.5 | -9.47 | 0.18 | -0.07 | -6.58 | |
| EV to operating cash flow | -31.32 | -12.46 | 0.2 | -0.07 | -7.87 | |
| EV to free cash flow | -30.55 | -11.46 | 0.2 | -0.06 | -6.95 | |
| Earnings yield | -0.02 | -0.1 | -0.21 | -0.51 | -0.15 | |
| Free cash flow yield | -0.03 | -0.08 | -0.19 | -0.55 | -0.14 | |
| Debt to equity | -4.52 | -1.8 | 0.12 | 0.11 | 0.13 | |
| Debt to assets | 1.28 | 2.25 | 0.11 | 0.1 | 0.12 | |
| Net debt to EBITDA | 10.36 | 1.03 | 5.01 | 2 | 0.35 | |
| Current ratio | 11.68 | 4.05 | 16.88 | 15.69 | 14.02 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.7 | 0.74 | 0.9 | 0.97 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.44 | 1.99 | 1.27 | 1.55 | 0 | |
| Research and developement to revenue | 1.3 | 5.54 | 3.9 | 3.4 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.09 | 0.02 | 0.13 | 0.13 | |
| Capex to revenue | -0.03 | -0.46 | -0.07 | -0.51 | 0 | |
| Capex to depreciation | -0.59 | -3.19 | -0.69 | -3.02 | -2.97 | |
| Stock based compensation to revenue | 0.1 | 0.51 | 0.37 | 0.76 | 0 | |
| Graham number | 5.19 | 22.73 | 88.93 | 111.28 | 23.12 | |
| ROIC | 0.12 | 1.19 | 0.21 | -1.5 | -0.72 | |
| Return on tangible assets | -0.1 | -0.85 | -0.2 | -0.2 | -0.41 | |
| Graham Net | -2.15 | -6.46 | 38.24 | 33.19 | 5.66 | |
| Working capital | 86.01M | 39.55M | 265.91M | 239.94M | 204.78M | |
| Tangible asset value | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | |
| Net current asset value | -30.49M | -78.7M | 250.71M | 221.9M | 190M | |
| Invested capital | 0 | 0 | 0 | 0.05 | 0.07 | |
| Average receivables | 722.5K | 1.05M | 1.23M | 766.5K | 23.5K | |
| Average payables | 707K | 1.35M | 1.77M | 893.5K | 1.66M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 29.03 | 51.1 | 39.85 | 0.95 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 12.57 | 7.14 | 9.16 | 383.79 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.35 | 0.68 | -0.22 | -0.22 | -0.46 | |
| Capex per share | -0.03 | -0.26 | -0.16 | -1.42 | -0.36 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0.04 | 0.01 | 0.02 | 0 | |
| Net income per share | -0.93 | -0.82 | -0.87 | -0.79 | -2.53 | |
| Operating cash flow per share | -0.81 | -0.73 | -0.62 | -0.65 | -2.03 | |
| Free cash flow per share | -1 | -0.93 | -0.68 | -0.71 | -2.33 | |
| Cash per share | 9.17 | 7.33 | 7.46 | 7.03 | 6.6 | |
| Book value per share | 11.81 | 9.19 | 8.43 | 7.76 | 7.15 | |
| Tangible book value per share | 11.81 | 9.19 | 8.43 | 7.76 | 7.15 | |
| Share holders equity per share | 11.81 | 9.19 | 8.43 | 7.76 | 7.15 | |
| Interest debt per share | 0.61 | 0.52 | 0.54 | 0.54 | 0.5 | |
| Market cap | 592.87M | 487.35M | 225.62M | 260.38M | 718.52M | |
| Enterprise value | 456.32M | 428.2M | 129.14M | 168.64M | 682.29M | |
| P/E ratio | -5.91 | -4.63 | -2.01 | -2.53 | -2.2 | |
| Price to sales ratio | 6.44K | 399.8 | 1.39K | 520.76 | 0 | |
| POCF ratio | -27.15 | -20.69 | -11.34 | -12.39 | -10.94 | |
| PFCF ratio | -22.01 | -16.27 | -10.27 | -11.33 | -9.55 | |
| P/B Ratio | 1.86 | 1.65 | 0.83 | 1.04 | 3.11 | |
| PTB ratio | 1.86 | 1.65 | 0.83 | 1.04 | 3.11 | |
| EV to sales | 4.96K | 351.27 | 797.15 | 337.27 | 0 | |
| Enterprise value over EBITDA | -19.67 | -16.82 | -4.8 | -7.02 | -8.66 | |
| EV to operating cash flow | -20.9 | -18.18 | -6.49 | -8.02 | -10.39 | |
| EV to free cash flow | -16.94 | -14.29 | -5.88 | -7.34 | -9.07 | |
| Earnings yield | -0.04 | -0.05 | -0.12 | -0.1 | -0.11 | |
| Free cash flow yield | -0.05 | -0.06 | -0.1 | -0.09 | -0.1 | |
| Debt to equity | 0.11 | 0.1 | 0.11 | 0.11 | 0.13 | |
| Debt to assets | 0.1 | 0.09 | 0.1 | 0.1 | 0.12 | |
| Net debt to EBITDA | 5.89 | 2.32 | 3.58 | 3.82 | 0.46 | |
| Current ratio | 15.69 | 20.1 | 17.2 | 17.14 | 14.02 | |
| Interest coverage | 0 | -263.92 | -83.61 | -33.33 | 0 | |
| Income quality | 0.87 | 0.89 | 0.71 | 0.82 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 79.65 | 6.75 | 50.41 | 16.11 | 0 | |
| Research and developement to revenue | 190.52 | 15.9 | 126.06 | 37.88 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.23 | 0.27 | 0.1 | 0.09 | 0.15 | |
| Capex to revenue | -55.39 | -5.26 | -12.75 | -3.93 | 0 | |
| Capex to depreciation | -2.7 | -8.2 | -2.49 | -2.23 | -3.19 | |
| Stock based compensation to revenue | 40.55 | 3.23 | 26.68 | 9.04 | 0 | |
| Graham number | 15.7 | 13 | 12.84 | 11.77 | 20.17 | |
| ROIC | -0.52 | -0.15 | -0.39 | -0.43 | -0.54 | |
| Return on tangible assets | -0.07 | -0.08 | -0.09 | -0.09 | -0.31 | |
| Graham Net | 7.9 | 6.43 | 6.52 | 6.14 | 5.66 | |
| Working capital | 239.94M | 230.96M | 232.19M | 218.91M | 204.78M | |
| Tangible asset value | 319.11M | 296.06M | 272.52M | 251.44M | 231.34M | |
| Net current asset value | 221.9M | 214.18M | 216.1M | 203.76M | 190M | |
| Invested capital | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | |
| Average receivables | 419K | 23.5K | 0 | 0 | 0 | |
| Average payables | 1.86M | 1.34M | 3M | 2.4M | 2.4M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 45.98 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.96 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.08 | -0.09 | -0.1 | -0.1 | -0.35 | |
| Capex per share | -0.19 | -0.2 | -0.06 | -0.06 | -0.3 |
FDMT Frequently Asked Questions
What is 4D Molecular Therapeutics, Inc. stock symbol ?
4D Molecular Therapeutics, Inc. is a US stock , located in Emeryville of Ca and trading under the symbol FDMT
Is 4D Molecular Therapeutics, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $38. The lowest prediction is $36 and the highest is $40
What is FDMT stock prediction ?
What is 4D Molecular Therapeutics, Inc. stock quote today ?
4D Molecular Therapeutics, Inc. stock price is $17.26 today.
Is 4D Molecular Therapeutics, Inc. stock public?
Yes, 4D Molecular Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 346.36K
- Market Capitalization 573.63M
- Employee 140
- CEO Dr. David H. Kirn M.D.
- Headquarters EmeryVille,CA,US
- IPO Date 2020-12-11
-
Website
https://www.4dmoleculartherapeutics.com 
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
